Ipinzan

Metformin Hydrochloride and Vildagliptin, the active ingredients in Ipinzan, are a biguanide and a DPP‑4 inhibitor presented as oral tablets for oral use. They are indicated for the treatment of type 2 diabetes mellitus in adult patients when diet, exercise, and monotherapy are insufficient. The combination improves glycemic control by reducing hepatic glucose output and enhancing insulin secretion in a glucose‑dependent manner.

GNH USA supplies Ipinzan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets.

Ipinzan, a fixed‑dose combination of metformin and vildagliptin, is employed in the management of type 2 diabetes mellitus. - Type 2 diabetes mellitus: lowers fasting plasma glucose and improves overall glycemic control. - Type 2 diabetes mellitus (post‑prandial): reduces post‑prandial glucose excursions. - Type 2 diabetes mellitus (HbA1c): helps achieve target HbA1c levels when added to diet and exercise.

The most frequently reported adverse reactions with Ipinzan involve the gastrointestinal system, while rare but serious events may also occur.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Diarrhea: loose stools occurring intermittently. - Abdominal discomfort: cramping or pain in the stomach area. - Headache: mild to moderate head pain. - Metallic taste: transient alteration in taste perception. - Vomiting: occasional episodes of expulsion of stomach contents.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal accumulation of lactate. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Hepatic dysfunction: abnormal liver enzyme elevations. - Anaphylactic reaction: acute allergic response requiring immediate care.

When prescribing Ipinzan, clinicians should consider several precautionary measures to ensure patient safety. - Renal function assessment: evaluate eGFR before initiating and periodically thereafter. - Hepatic disease monitoring: use with caution in patients with liver impairment. - Hypoglycemia risk: monitor blood glucose when combined with insulin or sulfonylureas. - Pregnancy and lactation: avoid unless benefits outweigh potential risks. - Alcohol consumption: limit intake to reduce risk of lactic acidosis. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Ipinzan may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycemia. - Iodinated contrast media: may precipitate metformin‑associated lactic acidosis in renal impairment. - Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt hypoglycemia warning signs. - Diuretics (thiazides): can affect renal clearance of metformin.